Latest Headlines

  1. BioSig PURE EP System Featured In The Editorial Of EP Lab Digest 1/14/2021

    BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the PURE EP™ System was featured in the January issue of EP Lab Digest

  2. Dual Detector Enables Sensitive Determination Of Molecular Weight Distribution 1/14/2021

    Testa Analytical Solutions e.K reports on the development and OEM supply of a novel combination refractive index / viscometry detector for Brookhaven Instruments Corporation (Holtsville, NY, USA).

  3. Web Based Digital Sample Management 1/14/2021

    Ziath has introduced a new version of DataPaq 5 (DP5) - its versatile web-based software product that allows scientists to directly read 2D-barcoded tubes at the point of sample storage or retrieval

  4. Safe, Simple and Economical Method for Freezing Organoids 1/13/2021

    AMSBIO reports how the internationally renowned Hans Clevers Lab at the Hubrecht Institute, Netherlands used their CELLBANKER® reagent when they needed to freeze down their organoids at short notice ahead of the COVID-19 spring lockdown.

  5. Heparan Sulfate Products for COVID-19 Infection, Disease & Therapeutics Research 1/13/2021

    AMSBIO offer a wide range of Heparan Sulfate antibodies, enzymes, standards and ready-to-use Heparanase activity assays for researchers seeking to better understand COVID-19 and thereby to combat the pandemic. Heparan Sulfate (HS) is increasingly recognised as a key factor in infection by the SARS-CoV-2 virus, which is the cause of the current COVID-19 Coronavirus pandemic. Using HS antibodies from AMSBIO, researchers have demonstrated that Heparanase enzyme contributes to the pathogenesis of COVID-19, with both Heparanase activity and HS levels being elevated in plasma of Covid-19 patients.

  6. InterVenn Receives Foundational Patent, CLIA Lab Certification To Develop Clinical Glycoproteomics Solutions 1/13/2021

    InterVenn Biosciences, the leader in glycoproteomics, today announced the accomplishment of multiple milestones in advancing the world’s first glycoproteomics-based LDT(Lab-Developed Test).

  7. Variantyx Surpasses 2,500 Genomes Analyzed, Highlights The Value Of Its WGS-Based Testing Methodology 1/12/2021

    Clinicians at Variantyx, a leader in high complexity hereditary disease testing, recently completed analysis of their 2,500th patient genome.

  8. Othram Launches KinSNP™ Priority Service For Rapid Familial Relationship Testing 1/12/2021

    Othram, the leading forensic sequencing laboratory for law enforcement, has announced a new priority service, KinSNP™, which enables rapid confirmation or exclusion of candidate relationships between an unknown subject and potential relatives in support of forensic genetic genealogy applications

  9. FDA Grants ADVAITE Emergency Use Authorization For RapCov™ Rapid COVID-19 Test 1/12/2021

    The U.S. Food and Drug Administration has granted Emergency Use Authorization (EUA) to one of the first U.S.-manufactured serology tests designed by ADVAITE Inc., an innovative biotech company developing novel point-of-care assays to help with combatting COVID-19

  10. Quanterix Receives FDA Emergency Use Authorization For SARS-CoV-2 N Protein Antigen Test 1/11/2021

    Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa SARS-CoV-2 N Protein Antigen Test that can be run on the Simoa HD-X Analyzer, a fully automated high-throughput immunoassay instrument